DK2332986T3 - Antistof som binder til H-1 parvovirus - Google Patents

Antistof som binder til H-1 parvovirus

Info

Publication number
DK2332986T3
DK2332986T3 DK09015373.5T DK09015373T DK2332986T3 DK 2332986 T3 DK2332986 T3 DK 2332986T3 DK 09015373 T DK09015373 T DK 09015373T DK 2332986 T3 DK2332986 T3 DK 2332986T3
Authority
DK
Denmark
Prior art keywords
parvovirus
binds
antibody
Prior art date
Application number
DK09015373.5T
Other languages
English (en)
Inventor
Barbara Leuchs
Kathrin Kuerschner
Andrea Kern
Marcus Mueller
Silvia Muensterman
Jean Rommelaere
Original Assignee
Deutsches Krebsforsch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK2332986T3 publication Critical patent/DK2332986T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/015Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK09015373.5T 2009-12-11 2009-12-11 Antistof som binder til H-1 parvovirus DK2332986T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09015373.5A EP2332986B1 (en) 2009-12-11 2009-12-11 Antibody that binds to H-1 parvovirus

Publications (1)

Publication Number Publication Date
DK2332986T3 true DK2332986T3 (da) 2013-12-16

Family

ID=42072902

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09015373.5T DK2332986T3 (da) 2009-12-11 2009-12-11 Antistof som binder til H-1 parvovirus

Country Status (8)

Country Link
US (1) US8828400B2 (da)
EP (2) EP2332986B1 (da)
JP (1) JP5755239B2 (da)
AU (1) AU2010330349B2 (da)
CA (1) CA2781796C (da)
DK (1) DK2332986T3 (da)
ES (1) ES2438774T3 (da)
WO (1) WO2011069614A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2451844B1 (en) 2009-07-10 2015-04-22 Innate Pharma Tlr3 binding agents
DK2332986T3 (da) * 2009-12-11 2013-12-16 Deutsches Krebsforsch Antistof som binder til H-1 parvovirus
WO2013178736A1 (en) 2012-05-31 2013-12-05 Innate Pharma Tlr3 binding agents
EP3108892A1 (en) * 2015-06-23 2016-12-28 Deutsches Krebsforschungszentrum Parvovirus formulation for treating tumors
JP6608969B2 (ja) * 2015-06-23 2019-11-20 ドイッチェス・クレープスフォルシュングスツェントルム パルボウイルスを大規模生産および精製するための方法
CN109627331B (zh) * 2019-01-22 2022-03-29 长春西诺生物科技有限公司 一种抗犬细小病毒抗体的重链、轻链可变区及基因工程抗体
AU2020321376A1 (en) 2019-07-30 2022-02-03 Elanco Us Inc. Parvovirus antibodies for veterinary use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010294A1 (en) 1992-10-23 1994-05-11 New York University Human monoclonal antibodies to human parvovirus and methods of making and using thereof
DK2332986T3 (da) * 2009-12-11 2013-12-16 Deutsches Krebsforsch Antistof som binder til H-1 parvovirus

Also Published As

Publication number Publication date
US20130028913A1 (en) 2013-01-31
ES2438774T3 (es) 2014-01-20
JP5755239B2 (ja) 2015-07-29
EP2332986A1 (en) 2011-06-15
CA2781796C (en) 2016-02-02
AU2010330349B2 (en) 2013-09-19
WO2011069614A1 (en) 2011-06-16
EP2509998A1 (en) 2012-10-17
US8828400B2 (en) 2014-09-09
EP2332986B1 (en) 2013-10-09
AU2010330349A1 (en) 2012-06-28
JP2013513358A (ja) 2013-04-22
CA2781796A1 (en) 2011-06-16

Similar Documents

Publication Publication Date Title
CY2019004I2 (el) Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY2022012I2 (el) Anti-ifnar1 αντισωματα me μειωμενη συγγενεια προσδετη fc
CY2019017I1 (el) Cgrp αντισωματα
BRPI1014262A2 (pt) anticorpos específicos para caderina-17
EP2473531A4 (en) Anti-gitr antibodies
BRPI0907237A2 (pt) Anticorpo anti-cldn6
HRP20171011T1 (hr) ANTI-eMET ANTITIJELO
SMT201700083B (it) Anticorpi monoclonali
BRPI0923359A2 (pt) Anticorpos anti-igf
BRPI0907532A2 (pt) Anticorpos anti-c5ar humanizados
PT2406284T (pt) Anticorpos anti-bcma
HUE056626T2 (hu) Antitestkészítmény
BRPI0916973A2 (pt) anticorpos para ccr2
IL212175B (en) Muc1* antibodies
BRPI0906877A2 (pt) Anticorpos anti-trkb aperfeiçoados
BRPI1011005A2 (pt) anticorpos anti-epcam
EP2482848A4 (en) Endoglin antibodies
IL232053B (en) Antibody formulations
IL229618B (en) Isolated antibody that binds fcrn
DK3653645T3 (da) Monoklonal interleukin-31-antistof
BR112013016917A2 (pt) ligantes que ligam receptor de tgf-beta ii.
BRPI0917204A2 (pt) variantes estruturais de anticorpos para melhores características terapêuticas
EP2181121A4 (en) CHIMÄRE ANTIGENE
HUE042898T2 (hu) Antitestek, amelyek kötnek CSF1R-t
CR20170001A (es) Anticuerpos anti factor d humanizados